Russian Journal of BiotherapyRussian Journal of BiotherapyРоссийский биотерапевтический журнал1726-97841726-9792Publishing House ABV Press82810.17650/1726-9784-2016-15-3-95-98BRIEF REPORTКРАТКИЕ СООБЩЕНИЯQUANTITATIVE ASSESSMENT OF BETA-III TUBULIN EXPRESSION IN LUNG ADENOCARCINOMA AND SQUAMOUS CELL CARCINOMAКОЛИЧЕСТВЕННАЯ ОЦЕНКА ЭКСПРЕССИИ БЕТА-Ш-ТУБУЛИНА В ТКАНЯХ АДЕНОКАРЦИНОМЫ И ПЛОСКОКЛЕТОЧНОГО РАКА ЛЕГКОГОDavydovM. M.ДавыдовМ. М.
Russian Federation
MamichevI. A.МамичевИван Андреевич
Russian Federation
labmedchem@mail.ruDudkoE. A.ДудкоЕ. А.
Russian Federation
BogushE. A.БогушЕ. А.
Russian Federation
KirsanovV. Yu.КирсановВ. Ю.
Russian Federation
PolotskyB. E.ПолоцкийБ. Е.
Russian Federation
DavydovM. I.ДавыдовМ. И.
Russian Federation
BogushT. A.БогушТ. А.
Russian Federation
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России30092016153959810042018https://bioterapevt.abvpress.ru/jour/article/view/828

Background. Beta-III tubulin (TUBB3) is a tumor-specific isoform of the microtubule protein beta-tubulin. TUBB3 is considered to be a marker of adverse prognosis and tumor resistance to therapy with taxanes and Vinka alkaloids. Association between TUBB3 expression and histological type of the tumor has not been studied properly yet. Objective. The expression level of TUBB3 in non-small cell lung cancer biopsy specimens has been measured on 2 groups of patients with adenocarcinoma and squamous cell carcinoma. Materials and methods. The samples with adenocarcinoma (n = 43) and squamous cell carcinoma (n = 39) were converted to suspension, filtered, fixed with 4 % formaldehyde, stained with monoclonal antibodies for TUBB3 and DyLight 650-conjugated secondary antibodies to mouse IgG and analyzed by flow-cytometry. The method was developed in N.N. Blokhin Russian Cancer Research Center. Results. The average level of TUBB3 expression in the adenocarcinoma group is higher than in the squamous cell carcinoma group (33.1 ± 12.4 % of cells expressing the marker in adenocarcinoma vs. 26.0 ± 13.6 % in squamous cell carcinoma; differences were statistically significant). The average level of TUBB3 expression in adenocarcinoma is 29.7 ± 8.1 % in female and is 34.9 ± 13.9 % in male (differences statistically insignificant). Since the group of patients with adenocarcinoma was presented by both men and women, while the group of patients with squamous cell carcinoma was only men, from the analysis was excluded all female patients. Differences between the groups remained statistically significant. Conclusion. TUBB3 expression in tumor tissue does not depend on the gender, at least among patients with adenocarcinoma of the lung, and at the same time, the level of TUBB3 in adenocarcinoma tissue is higher in comparison with squamous cell carcinoma tissue.

немелкоклеточный рак легкогобета-Ш-тубулинаденокарцинома легкогоплоскоклеточный рак легкогопроточная цитофлуориметрияnon-small cell lung cancerbeta-III tubulinadenocarcinomasquamous cell carcinomaflow cytometryВладимирова Л.Ю., Кит О.И., Шолохова E.A. Роль гистологического и молекулярного анализа в выборе метода лечения немелкоклеточного рака легкого поздних стадий. Фарматека 2012; 241(8): 9-22.Travis W.D., Brambilla E., Nicholson A.G. et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015; 10(9): 1243-60. DOI: 10.1097/JTO.0000000000000630. PMID: 26291008.Hirsch F.R., Spreafico A., Novello S. et al. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 2008; 3(12): 1468-81. DOI: 10.1097/JTO.0b013e318189f551. PMID: 19057275.D’Addario G., Fruh M., Reck M. et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(3): 27-39. DOI: 10.1093/annonc/mdu199. PMID: 25115305.Azzoli C.G., Temin S., Aliff T. et al. 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small cell lung cancer. J Oncol Pract 2012; 8(1): 63-6. DOI: 10.1200/JOP.2011.000374. PMID: 22548014.Shaw A.T., Yeap B.Y., Mino-Kenudson M. et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27(26): 4247-53. DOI: 10.1200/JCO.2009.22.6993. PMID: 19667264.Shigematsu H., Lin L., Takahashi T. et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97(5): 339-46. PMID: 15741570.Bass A.J., Watanabe H., Mermel C.H. et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009; 41(11): 1238-42. DOI: 10.1038/ng.465. PMID: 19801978.Weiss J., Sos M.L., Seidel D. et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010; 2(62): 62-93. DOI: 10.1126/scitranslmed.3001451. PMID: 21160078.Богуш Т.А., Шатурова А.С., Дудко Е.А. и др. Количественная иммунофлуоресцент-ная оценка с использованием проточной цитофлуориметрии экспрессии эстрогено-вых рецепторов ß в солидных опухолях человека. Вестник Московского университета, сер. 2. Химия 2011; 52(4): 305-12.Saussede-Aim J., Matera E.L., Ferlini C. et al. Beta-3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway. Cell Motil Cytoskeleton 2009; 66(7): 378-88. DOI: 10.1002/cm.20377. PMID: 19466750.Reiman T., Lai R., Veillard A.S. et al. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol 2012; 23(1): 86-93. DOI: 10.1093/annonc/mdr033. PMID: 21471564.